Fast eating is not good for the gut
However, semaglutide remains an excellent, FDA-approved option for many patients, particularly those whose insurance covers Wegovy preferentially, those with established cardiovascular disease where semaglutides cardiovascular risk reduction FDA approval is clinically relevant, or those who have previously responded well to semaglutide
Participants in trials experienced significant reductions in body weight, with many achieving a weight loss of 15% or more of their initial body weight
The latter, while providing valuable real-world signals, are inherently susceptible to confounding by indication and selection bias, as patient characteristics and co-morbidities may differ significantly between treatment groups
Using semaglutide as a runner requires careful management of diet, hydration, and training intensity